Articles by Lynn D. Torbeck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Lynn D. Torbeck

The Role of Statistical Significance Tests

Mar 1, 2010

Statistical Solutions: %RSD: Friend or Foe?

When to use percent relative standard deviation—and how to do so correctly.
Jan 2, 2010

When to use percent relative standard deviation—and how to do so correctly.

Can We Save the Technical Conference?

Dumbed-down presentations and pooer speaker selections are destroying a valuable industry tool.
Dec 2, 2009

Dumbed-down presentations and poor speaker selections are destroying a valuable industry tool.

Statistical Solutions: Square Root of (N) + 1 Sampling Plan

Is the square root of (N) + 1 a statistically valid scheme?
Oct 2, 2009

Is the square root of (N) + 1 a statistically valid scheme?

FDA Perspectives: An Overview of the CDER Drug Recall Root Cause Research Project

Aug 2, 2009

This article provides an overview of the drug Recall Root Cause Research (RRCR) project, an initiative of the US Food and Drug Administration's Center for Drug Evaluation and Research.

Statistical Implications of the CGMPs: A 30-Year Retrospective

This article looks at the current good manufacturing practice regulations from a statistical perspective while addressing their requirements and implications and inviting the industry to assess its past performance in meeting the regulations.
Jul 2, 2007

This article looks at the current good manufacturing practice regulations from a statistical perspective while addressing their requirements and implications and inviting the industry to assess its past performance in meeting the regulations.

The Sector Chart: A New Engineering Graphfor Pharmaceutical Processes

Apr 2, 2005

The author proposes a new analytical graphic, the sector chart, which presents data that cannot be adequately presented with current graphs.This chart combines features of zone charts with the basic principle of precontrol charts. It addresses engineering control and is superior for representing data such as beneficial and adverse trends.

In Defense of USP Singlet Testing

Feb 2, 2005

The United States Pharmacopeia should not change its philosophical position on singlet testing.

Preventing the Practice of Testing Into Compliance

Oct 1, 2002

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here